By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Protalex, Inc. 



Albuquerque  New Mexico  87190  U.S.A.
Phone: 505-260-1726 Fax:


SEARCH JOBS


Industry
Biotechnology






Company News
Protalex, Inc. (PRTX) Announces First Patient Dosed In European Phase Ib Study Of PRTX-100 For Immune Thrombocytopenia 1/7/2016 10:51:29 AM
Protalex, Inc. (PRTX) Announces First Patient Dosed In U.S. Phase I/II Study Of PRTX-100 For Immune Thrombocytopenia 11/23/2015 8:32:25 AM
Protalex, Inc. (PRTX) Announces Presentation Of Preclinical Data With PRTX-100 Supporting Treatment Of Immune Thrombocytopenia At The American Society of Hematology 57th Annual Meeting And Exposition 11/11/2015 11:03:12 AM
Protalex, Inc. (PRTX) Announces Regulatory Approval To Initiate Phase Ib Trial Of PRTX-100 To Treat Immune Thrombocytopenia In France 10/5/2015 10:32:40 AM
Protalex, Inc. (PRTX) To Initiate Enrollment Of U.S. Phase I/II Trial Of PRTX-100 To Treat Immune Thrombocytopenia 9/3/2015 10:55:00 AM
Protalex, Inc. (PRTX) Announces Listing On OTCQB Exchange 7/21/2015 11:01:48 AM
Protalex, Inc. (PRTX) Receives Orphan Drug Designation From FDA For PRTX-100 To Treat Immune Thrombocytopenia 6/16/2015 9:48:39 AM
Protalex, Inc. (PRTX) Announces Findings From Final Cohort Of U.S. Phase Ib Trial Of PRTX-100 In Active Rheumatoid Arthritis Patients 4/16/2015 10:59:13 AM
Protalex, Inc. (PRTX) Announces FDA Acceptance Of Investigational New Drug Application For PRTX-100 To Treat Immune Thrombocytopenia 3/31/2015 11:33:04 AM
Protalex, Inc. (PRTX) Initiates Enrollment Of Phase I/II Continuation Trial Of PRTX-100 In Active Rheumatoid Arthritis Patients 3/12/2015 8:11:52 AM
1234567
//-->